Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

被引:135
作者
Deacon, CF
Danielson, P
Klarskov, L
Olesen, M
Holst, JJ
机构
[1] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark
[2] Univ Copenhagen, Panum Inst, Dept Expt Med, DK-2200 Copenhagen, Denmark
关键词
D O I
10.2337/diabetes.50.7.1588
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucose-dependent insulinotropic peptide (GIP) is known to be degraded by dipeptidyl peptidase TV (DPP IV), forming an inactive metabolite, but the extent of the enzyme's role in regulating the biological activity of GIP in vivo is still largely unknown. In nonfasted anesthetized pigs given an intravenous infusion of GIP, the intact peptide (determined by a novel NH2-terminally directed radioimmunoassay) accounts for only 14.5 +/- 2.5% of total immunoreactivity. This is increased (to 40.9 +/- 0.9%; P < 0.0001) by coadministration of valine-pyrrolidide (a specific DPP TV inhibitor) at a dose that completely inhibits plasma DPP TV activity. The plasma t(1/2) of intact GIP is prolonged by the inhibitor (from 3.3 +/- 0.3 to 8.1 +/- 0.6 min; P < 0.001), whereas the t(1/2) for COOH-terminal immunoreactivity is unaffected (13.2 +/- 0.5 and 11.5 +/- 0.8 min, pre- and postinhibitor). Measurement of arteriovenous concentration differences revealed that the liver, kidney, and extremities are the main sites of removal of exogenous intact GIP (organ extractions, 28.0 +/- 2.2, 26.3 +/- 5.7, and 21.8 +/- 3.0%, respectively). These organ extractions are reduced (P < 0.02) but not eliminated (kidney and extremities) by valine-pyrrolidide (to 6.5 +/- 4.6, 14.1 +/- 3.1, and 13.9 +/- 2.4%, respectively). Valine-pyrrolidide potentiates the insulinotropic effect of GIP (P < 0.02), resulting in an enhanced glucose disappearance rate (k, from 8.0 +/- 0.5 to 15.5 +/- 2.2%/min; P < 0.01) and a reduction in the glucose excursion after an intravenous glucose load (area under the curve, from 133 +/- 23 to 75 +/- 9 min . mmol/l; P < 0.05). These results suggest that DPP IV plays an important role in GIP metabolism but is not the sole enzyme responsible for its NH,terminal degradation. Nevertheless, DPP IV inhibition increases the proportion of intact peptide sufficiently to enhance its insulinotropic and antihyperglycemic effects.
引用
收藏
页码:1588 / 1597
页数:10
相关论文
共 52 条
[1]   INVIVO INHIBITION OF GLUCAGON-SECRETION BY PARACRINE BETA-CELL ACTIVITY IN MAN [J].
ASPLIN, CM ;
PAQUETTE, TL ;
PALMER, JP .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (01) :314-318
[2]   EFFECTS OF GASTRIC-INHIBITORY POLYPEPTIDE, VASOACTIVE INTESTINAL POLYPEPTIDE AND PEPTIDE HISTIDINE ISOLEUCINE ON THE SECRETION OF HORMONES BY ISOLATED MOUSE PANCREATIC-ISLETS [J].
BAILEY, CJ ;
WILKES, LC ;
CONLON, JM ;
ARMSTRONG, PH ;
BUCHANAN, KD .
JOURNAL OF ENDOCRINOLOGY, 1990, 125 (03) :375-379
[3]   Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats [J].
Balkan, B ;
Kwasnik, L ;
Miserendino, R ;
Holst, JJ ;
Li, X .
DIABETOLOGIA, 1999, 42 (11) :1324-1331
[4]   ABSENCE OF HEPATIC EXTRACTION OF GASTRIC-INHIBITORY POLYPEPTIDE IN CONSCIOUS DOGS [J].
CHAP, Z ;
ODORISIO, TM ;
CATALAND, S ;
FIELD, JB .
DIGESTIVE DISEASES AND SCIENCES, 1987, 32 (03) :280-284
[5]   Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide [J].
Deacon, CF ;
Nauck, MA ;
Meier, J ;
Hücking, K ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3575-3581
[6]   Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig [J].
Deacon, CF ;
Hughes, TE ;
Holst, JJ .
DIABETES, 1998, 47 (05) :764-769
[7]   BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].
DEACON, CF ;
NAUCK, MA ;
TOFTNIELSEN, M ;
PRIDAL, L ;
WILLMS, B ;
HOLST, JJ .
DIABETES, 1995, 44 (09) :1126-1131
[8]   DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].
DEACON, CF ;
JOHNSEN, AH ;
HOLST, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957
[9]   Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig [J].
Deacon, CF ;
Pridal, L ;
Klarskov, L ;
Olesen, M ;
Holst, JJ .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1996, 271 (03) :E458-E464
[10]   Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism [J].
Ding, WG ;
Renstrom, E ;
Rorsman, P ;
Buschard, K ;
Gromada, J .
DIABETES, 1997, 46 (05) :792-800